Evidence map›Paper›PMID 35661944›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2022

Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.

Joe Yeong, Huey Yew Jeffrey Lum, Chong Boon Teo, Benjamin Kye Jyn Tan, Yiong Huak Chan, Ryan Yong Kiat Tay, Joan Rou-En Choo, Anand D Jeyasekharan, Qing Hao Miow, Lit-Hsin Loo and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Real-world characterization of PD-L1 expression in patients with advanced esophagogastric adenocarcinoma in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Observational
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Observational
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Joe Yeong *Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore, Singapore.
Huey Yew Jeffrey Lum *Department of Pathology, National University Health System, Singapore, Singapore.
Chong Boon Teo *Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Benjamin Kye Jyn TanYong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Yiong Huak ChanBiostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Ryan Yong Kiat TayYong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Joan Rou-En ChooDepartment of Haematology-Oncology, National University Cancer Institute, Singapore, National University Hospital, Singapore, Singapore.
Anand D JeyasekharanDepartment of Haematology-Oncology, National University Cancer Institute, Singapore, National University Hospital, Singapore, Singapore.
Qing Hao MiowDepartment of Haematology-Oncology, National University Cancer Institute, Singapore, National University Hospital, Singapore, Singapore.
Lit-Hsin LooBioinformatics Institute, Agency for Science, Technology, and Research, Singapore, Singapore.
Wei Peng Yong *Department of Haematology-Oncology, National University Cancer Institute, Singapore, National University Hospital, Singapore, Singapore.
Raghav Sundar *Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. mdcragh@nus.edu.sg.
National University of Singapore · SGNational University Cancer Institute, Singapore · SGNational University Hospital · SGAgency for Science, Technology and Research · SGNational University Health System · SGSingapore General Hospital · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICI) are now standard-of-care treatment for patients with metastatic gastric cancer (GC). To guide patient selection for ICI therapy, programmed death ligand-1 (PD-L1) biomarker expression is routinely assessed via immunohistochemistry (IHC). However, with an increasing number of approved ICIs, each paired with a different PD-L1 antibody IHC assay used in their respective landmark trials, there is an unmet clinical and logistical need for harmonization. We investigated the interchangeability between the Dako 22C3, Dako 28-8 and Ventana SP-142 assays in GC PD-L1 IHC.

methodsIn this cross-sectional study, we scored 362 GC samples for PD-L1 combined positive score (CPS), tumor proportion score (TPS) and immune cells (IC) using a multiplex immunohistochemistry/immunofluorescence technique. Samples were obtained via biopsy or resection of gastric cancer.

resultsThe percentage of PD-L1-positive samples at clinically relevant CPS ≥ 1, ≥ 5 and ≥ 10 cut-offs for the 28-8 assay were approximately two-fold higher than that of the 22C3 (CPS ≥ 1: 70.3 vs 49.4%, p < 0.001; CPS ≥ 5: 29.1 vs 13.4%, p < 0.001; CPS ≥ 10: 13.7 vs 7.0%, p = 0.004). The mean CPS score on 28-8 assay was nearly double that of the 22C3 (6.39 ± 14.5 vs 3.46 ± 8.98, p < 0.001). At the clinically important CPS ≥ 5 cut-off, there was only moderate concordance between the 22C3 and 28-8 assays.

conclusionOur findings suggest that scoring PD-L1 CPS with the 28-8 assay may result in higher PD-L1 scores and higher proportion of PD-L1 positivity compared to 22C3 and other assays. Until stronger evidence of inter-assay concordance is found, we urge caution in treating the assays as equivalent.

Indexed as

B7-H1 AntigenImmunotherapyStomach NeoplasmsBiomarkers, TumorCross-Sectional StudiesHumansImmunohistochemistryB7-H1 AntigenBiomarkers, TumorCD274 protein, humanBiomarkersImmune checkpoint inhibitorsImmunotherapyStomach neoplasmsTumor

Identifiers

PMID35661944
PMCPMC9226082
OpenAlexW4282032524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.